NVO
NOVO NORDISK A S
NYSE: NVO · Bagsvaerd Denmark, G7 · Healthcare
$39.42-1.04 (-2.57%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$34.76 – $77.31
Avg Volume17.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$39.42-66.4%
Pipeline

Drug candidates sponsored by NOVO NORDISK A S · ClinicalTrials.gov

45 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Unnamed
Diabetes+3 more
Completed
2005-06past
1
Phase 4insulin aspart
Diabetes+1 more
Completed
2006-10past
2
Phase 4biphasic insulin aspart
Diabetes+2 more
Completed
2008-11-15past
3
Phase 4activated recombinant human factor VII
Congenital Bleeding Disorder+9 more
Completed
2012-01past
6
Phase 4insulin detemir
Diabetes+2 more
Completed
2012-05past
8
Phase 4biphasic insulin aspart 30
Diabetes+2 more
Completed
2013-01past
2
Phase 4liraglutide
Diabetes+2 more
Completed
2017-05-02past
8
Phase 3biphasic insulin aspart 50
Diabetes+2 more
Completed
2003-12-17past
2
Phase 3Unnamed
Diabetes+3 more
Completed
2004-02past
1
Phase 3estradiol, 25 mcg
Menopause+1 more
Terminated
2004-03-17past
1
Phase 3inhaled human insulin
Diabetes+1 more
Completed
2004-12-14past
1
Phase 3insulin degludec/liraglutide
Diabetes+1 more
Completed
2014-03-11past
1
Phase 3somatropin
Growth Hormone Disorder+5 more
Completed
2016-09-30past
3
Phase 3turoctocog alfa
Congenital Bleeding Disorder+1 more
Completed
2017-08-16past
2
Phase 3insulin degludec
Diabetes+3 more
Completed
2019-02-13past
9
Phase 3Semaglutide 2.4 mg
Obesity
Completed
2023-10-16past
1
Phase 3semaglutide
Diabetes+4 more
Completed
2025-05-12past
12
Phase 3Semagludtide
Early Alzheimer's Disease
Completed
2025-09-16past
1
Phase 3Cagrilintide
Type 2 Diabetes+2 more
Completed
2025-10-01past
3
Phase 3Oral semaglutide
Diabetes Mellitus, Type 2+2 more
Active, not recruiting
2026-06-29
5
Phase 3Somapacitan
SGA+4 more
Active, not recruiting
2026-12-31
2
Phase 3Ziltivekimab
Myocardial Infarction
Recruiting
2028-11-14
1
Phase 1Unnamed
Diabetes+2 more
Completed
2005-09past
1
Phase 1estradiol, 10 mcg
Menopause+1 more
Completed
2007-05past
1
Phase 1anti-IL-20
Inflammation+1 more
Completed
2010-12past
1
Phase 1insulin 338 (GIPET I)
Diabetes+1 more
Completed
2013-08-19past
1
Phase 1Faster-acting insulin aspart
Diabetes+1 more
Completed
2014-06past
2
Phase 1Insulin 338
Healthy+2 more
Completed
2015-03-31past
1
Phase 1NNC0143-0406
Diabetes+1 more
Completed
2016-06past
1
Phase 1NNC0113-2023
Diabetes Mellitus, Type 2
Completed
2018-12-13past
1
Phase 1NNC0148-0287sema
Diabetes Mellitus, Type 2
Completed
2019-10-10past
1
Phase 1insulin degludec/insulin aspart
Healthy+1 more
Completed
2020-12-11past
2
Phase 1Insulin icodec
Diabetes Mellitus, Type 2
Completed
2021-09-27past
1
Phase 1Semaglutide D
Healthy Volunteers+2 more
Completed
2023-02-26past
1
Phase 1NNC0705-0001
Healthy Volunteers+1 more
Completed
2025-11-04past
1
N/AUnnamed
Diabetes+2 more
Completed
2011-09past
1
N/AUnnamed
Diabetes+3 more
Completed
2015-10past
1
N/AUnnamed
Metabolism and Nutrition Disorder+1 more
Completed
2015-11-12past
1
N/AUnnamed
Growth Disorder+1 more
Completed
2018-05-14past
1
N/AUnnamed
Growth Hormone Deficiency in Children
Completed
2019-04-25past
1
N/AEptacog alfa (activated)
Severe Postpartum Haemorrhage
Completed
2021-01-13past
1
N/AUnnamed
Obesity
Completed
2022-05-23past
1
N/AVagifem®
Postmenopausal Vaginal Atrophy
Completed
2022-07-31past
1
N/AUnnamed
Overweight+1 more
Completed
2025-08-25past
1
N/AUnnamed
Overweight+4 more
Completed
2025-12-19past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for NVO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.